No Data
CIRRUS: Interim Report 2024
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data From Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients With Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 Am Eastern Time
ZEISS Redefines Disease Management and Treatment Within the ZEISS Retina Workflow
Cirrus Logic Insiders Sell US$1.8m Of Stock, Possibly Signalling Caution
Cirrus Logic Celebrates 40 Years of Innovation and Excellence
Hong Kong stocks surge: Xirui rises more than 7% in the afternoon, with a significant increase in mid-term profits and aircraft deliveries reaching 287 units.
Xirui (2507.HK) rose more than 7% in the afternoon, closing at HK$19.86, with a total market value of HK$7.27 billion.
No Data
No Data